Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma (NCT07303283) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
China218 participantsStarted 2026-04-15
Plain-language summary
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to compare the efficacy and safety of Becotatug Vedotin and capecitabine as an adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. Patients must be informed of the investigational nature of this study and give written informed consent.
✓. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug.
Exclusion criteria
✕. Patients who could not tolerate or were allergic to Becotatug Vedotin.
✕. Patients with severe chronic or active infection that must be treated with systemic antibacterial, antifungal, or antiviral therapy before randomization, including but not limited to tuberculosis infection.
✕. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.
✕. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period).
✕. Interstitial lung disease or pneumonia requiring oral or intravenous steroid therapy within 1 year.
✕. Patients who are known to be intolerant or sensitive to any therapeutic agents.
✕. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \> 1.5×ULN), and emotional disturbance.